LIRRH Trial for the Right-sided Colon Cancer

Inclusion Criteria: * Age 18-75 years * ASA physical status ≤ III * Endoscopy and biopsy-proven colon adenocarcinoma * Contrast-enhanced abdominal CT showing primary tumor located in the ascending colon or proximal transverse colon (proximal one-third) * Pre-operative clinical stage: TanyNanyM0 * Able to understand the study protocol, willing to participate, and provide written informed consent Exclusion Criteria: * History of hypertensive crisis or hypertensive encephalopathy. * Severe cardiopulmonary insufficiency or any other contraindication to surgery. * Uncorrectable electrolyte disturbances (e.g., potassium, calcium, magnesium). * Evidence of significant bleeding diathesis or high hemorrhagic risk: * Prior intracranial or intraspinal hemorrhage. * Tumor invading major vessels with obvious bleeding risk. * Thrombotic or embolic event within 6 months before study treatment, or significant vascular disease (e.g., surgical-repair aortic aneurysm). * Clinically relevant hemoptysis or tumor bleeding of any cause within 1 month before screening. * Therapeutic-dose anticoagulation within 2 weeks before study treatment (except low-molecular-weight heparin). * Antiplatelet therapy within 10 days before study treatment (e.g., aspirin \> 325 mg/day, clopidogrel \> 75 mg/day, dipyridamole, ticlopidine, cilostazol). * Active tuberculosis. * Any active autoimmune disease or history of autoimmune disease with expected recurrence (including but not limited to SLE, RA, autoimmune hep…